TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01297-0 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Xin'an Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Dioxygenases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Beijing Municipal Science and Technology Commission, the Major Program of the National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Despite the high incidence of tet methylcytosine dioxygenase 2 (TET2) mutations in acute myeloid leukemia (AML), the prognostic implications of these mutations in three AML risk groups based on the 2022 ELN AML risk classification are still unclear. A total of 502 consecutive de novo AML patients who had next-generation sequencing data available between March 2011 and July 2021 at the Peking University Institute of Hematology were enrolled in this study. Univariate and multivariate Cox regression analyses were performed to explore the prognostic impact of TET2 mutations in the above cohort and the Beat AML cohort. Of the 502 total AML patients, 76 (15.1%) carried TET2 mutations. Multivariate analysis revealed TET2 mutations as independent risk factor for overall survival (OS) in both the total AML cohort (OR = 1.649, p = 0.009) and in the 2022 ELN intermediate-risk cohort (HR = 1.967, p = 0.05). Analysis of RNA-seq data from the Beat AML study revealed 1042 differentially expressed genes (DEGs) between the TET2-mutant and TET2 wild-type groups. The results of enrichment analysis indicated the DEGs to be notably enriched in categories related to the PI3K-Akt signaling pathway. Collectively, our findings indicate that mutations in TET2 are prognostically disadvantageous in AML patients. Assessment of TET2 mutational status contributes to the stratification of intermediate-risk AML patients. Multiple genes and pathways of potential therapeutic relevance may be differentially modulated by TET2 mutations in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhim…
- Peking-Tsinghua Center for Life Sciences, Beijing, 100044, China.
- Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing, China.
- Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing, China. zhaoxiaosu1977@126.com.
Förderung
- the Beijing Municipal Science and Technology Commission
- the Major Program of the National Natural Science Foundation of China
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Pan, X., Chang, Y., Ruan, G., Zhou, S., Jiang, H., Jiang, Q., Huang, X., & Zhao, X. S. (2024). TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01297-0
Vancouver
Pan X, Chang Y, Ruan G, Zhou S, Jiang H, Jiang Q, et al. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01297-0
BibTeX
@article{Pan2024,
author = {Pan, Xin'an and Chang, Yingjun and Ruan, Guorui and Zhou, Songhai and Jiang, Hao and Jiang, Qian and Huang, Xiaojun and Zhao, Xiao-Su},
title = {TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01297-0}
}
EUVIMED